BORDEAUX, France, October 31, 2014 /PRNewswire/ --
- New cash raised: M€ 22.2
- Bridge loans conversion: M€ 13.7
- Europlasma secures liquidity for financing the on-going
business operations, for capturing its future growth opportunies
and for deleveraging its balance sheet
Europlasma, the French company with a global reach that
designs, builds and operates plasma solutions for renewable energy
generation and hazardous waste recovery, announces the success of
its capital increase issue.
Commenting on the success of the operation, Managing director
Jean-Eric Petit said: "I am most
grateful to all the investors, longstanding and new shareholders,
who have ensured the success of this operation despite challenging
market conditions, thereby testifying to their confidence in
Europlasma. I would also like to thank our directors and all our
employees, who demonstrate their commitment and dedication to our
group on a daily basis. This capital increase is a major step for
Europlasma and marks the start of a new development phase. We now
have a financial structure that matches our strategy for proactive
value creation and we are more than ever determined to implement
our technologies, leverage our group's growth potential and carry
out an ambitious business plan to meet current and future energy
and environmental challenges."
Fundraising of M€ 35.9
Total demand for both the rights issue and the reserved capital
increase amounted to M€ 35.9, of which
M€ 22.2 were new cash and M€ 13.7 were the totality of the
outstanding bridge loans, converted by the reference shareholder
and financial partners.
The funds raised under this operation will enable the Europlasma
Group to:
- Provide visibility over the financing of its short and medium
term operations;
- Seize the growth opportunities presented to the company in each
of its businesses including financing its share of investment in
the next CHO Power plant by the end of 2015 based on the
provisional roll-out schedule;
- Deleverage the balance sheet and position the Group into a net
positive cash situation.
The proceeds of the operations, including the issue premium,
amounted to M€ 35.9 and led to the creation of 44.886.782 new
shares at the unit price of €0.80, bringing the number of shares
comprising Europlasma's capital to 68.023.795.
24,028,962 new shares were subscribed by irrevocable
entitlement. Reducible subscription requests accounted for
19,982,820 new shares, of which 16,268,300 shares accounted for the
bridge loans conversion in Europlasma shares, and could only be
partly allocated, in the amount of 6,962,037 new shares.
Accordingly, the Company made use of the authorisation granted by
the annual general meeting on 1 September
2014 to fulfil requests to convert bridge loans granted to
the company into shares, and carried out a reserved capital
increase of M€ 8.1 at an issue price of €0.80/share.
The rights issue was structured by ARKEON Finance, who assisted
in its execution.
Settlement and delivery of new shares
The settlement and delivery of new shares and their listing on
Alternext will be carried out on 4 November. The new shares will
carry voting and dividend rights from the date of issue. They will
immediately be fungible with the Company's existing shares and
traded under the same market listing under the ISIN code
FR0000044810.
Reminder: subscribers willing to exercise ISF benefit should
request evidence of their subscription from Europlasma by mail at
actionnaires@europlasma.com or by post Europlasma attention to Anne
BORDERES, 471 route de Cantegrit 40110 Morcenx France. This
evidence may be required by the French Tax office.
Issue of redeemable share purchase warrants
(BSAR)
On 6 November 2014, Europlasma
will issue redeemable share purchase warrants (BSAR) in two
tranches, allotted free of charge to each shareholder whose shares
will be registered at the close of trading on 5 November 2014. Each shareholder will receive
one "BSAR A" warrant and one "BSAR B" warrant per share held, to be
listed on Alternext under two separate listings.
Two BSAR A warrants will entitle holders to subscribe for one
new share at €0.80 per share, for a period of three years from
6 November 2014.
Four BSAR B warrants will entitle holders to subscribe for one
new share at €1.30 per share, for a period of five years from
6 November 2014.
Public information
The Prospectus, which received AMF approval no. 14-512 on
23 September 2014, comprises (i) the
Europlasma Registration Document filed on 26
August 2014 with the AMF under no. R. 14-051, (ii) a
securities note and (iii) a summary of the Prospectus (accompanying
the securities note). Copies of the Prospectus are available free
of charge from Europlasma's head office at 471 Route de Cantegrit
Est - BP 23 - F-40110 Morcenx, on the Company's website
(http://www.europlasma.com) and on the AMF website
(http://www.amf-france.org). Investors' attention is drawn to the
risk factors contained in section 3.4 of the Registration Document
and section 2 of the securities note.
About Europlasma
Europlasma is a French Group operating in the clean technologies
and renewable energy production industries. Founded in 1992 to
apply its proprietary plasma torch technology to hazardous waste
destruction, it is now built on the following three business
units:
- Europlasma is a world-wide supplier of plasma heating
systems and related applications
- CHO Power is a producer of electricity from waste and
biomass gasification.
- Inertam is the global specialist in the destruction and
recycling of asbestos and hazardous waste
http://www.europlasma.com [Alternext - NYSE Euronext Paris
- Mnemo : ALEUP - Isin : FR0000044810]
Warning
This press release does not constitute and shall not be
considered as constituting a public offer, an offer to purchase or
as an intention to solicit the interest of the public for a public
offering of any securities.
The information in this press release is not for publication or
distribution in the United States,
Canada, Australia or Japan. The distribution of this document in
these and certain other countries may be restricted by law. The
persons into whose possession this document comes should inform
themselves about and observe any such restrictions.
In particular: This document does not constitute an offer to sell
or the solicitation of an offer to buy the securities of EUROPLASMA
("EUROPLASMA" or the "Issuer") in the
United States or in any other jurisdiction of the United States. The securities referred to
herein may not be offered or sold in the
United States unless such securities are registered under,
or pursuant to an exemption from registration under, the US
Securities Act of 1933, as amended. The Issuer has not registered,
and does not intend to register, any of the securities referred to
herein in the United States and
does not intend to conduct a public offering of the securities in
the United States.
This press release does not constitute a prospectus within the
meaning of Directive 2003/71/EC of the European Parliament and the
Council of November 4th, 2003 (the
"Prospectus Directive"), as amended, to the extent such Directive
has been transposed in the relevant Member State of the European
Economic Area. With respect to the Member States of the European
Economic Area which have implemented the Prospectus Directive (each
a "Relevant Member State"), no action has been undertaken or will
be undertaken to make an offer to the public of the securities
requiring a publication of a prospectus in any Relevant Member
State, other than France. As a
result, the new or existing shares of the Issuer may not be offered
and will not be offered in any Relevant Member State other than
France, except (i) to any legal
entity which is a qualified investor as defined under the
Prospectus Directive, (ii) to fewer than 100, or, if the Relevant
Member State has implemented the relevant provisions of Directive
2010/73/EU, 150, natural or legal persons (other than qualified
investors as defined in the Prospectus Directive) as permitted
under the Prospectus Directive; or (iii) in any other circumstances
not requiring the Issuer to publish a prospectus as provided under
Article 3(2) of the Prospectus Directive and/or regulations
applicable in the Relevant Member State.
For the purposes of this provision, an "offer to the public" in
relation to the new or existing shares of the Issuer in any
Relevant Member State means the communication in any form and by
any means of sufficient information on the terms of the offer and
the new or existing shares of the Issuer to be offered so as to
enable an investor to decide to purchase the new or existing shares
of the Issuer, as the same may be varied in that Member State by
any measure implementing the Prospectus Directive in that Member
State.
In the United Kingdom, this
document does not constitute an approved prospectus for the purpose
of and as defined in section 85 of the Financial Services and
Markets Act 2000 (as amended) (the "FSMA"), has not been prepared
in accordance with the Prospectus Rules issued by the UK Financial
Conduct Authority (the "FCA") pursuant to section 73A of the FSMA
and has not been approved by or filed with the FCA or any other
authority which would be a competent authority for the purposes of
the Prospectus Directive. The new and existing shares in the Issuer
may not be offered or sold and will not be offered or sold to the
public in the United Kingdom
(within the meaning of sections 85 and 102B of the FSMA) save in
the circumstances where it is to be lawful to do so without an
approved prospectus (within the meaning of section 85 of the FSMA)
being made available to the public before the offer is made.
This document is for distribution in the United Kingdom only to persons who (i) have
professional experience in matters relating to investments falling
within section 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (as amended, the "Financial
Promotion Order"), (ii) are persons falling within sections
49(2)(a) to (d) ("high net worth bodies corporate, unincorporated
associations etc") of the Financial Promotion Order, or (iii) are
persons otherwise permitted by law to receive it (all such persons
together being referred to as "Relevant Persons"). In the
United Kingdom this document is
directed only at Relevant Persons and must not be distributed to,
acted on or relied on by persons who are not Relevant Persons. Any
investment or investment activity to which this document relates is
available in the United Kingdom
only to Relevant Persons and will be engaged in only with Relevant
Persons.
EUROPLASMA
Jean-Eric PETIT - CEO
Estelle MOTHAY - CFO
Anne BORDERES - Shareholers & investors
contact
Tel: + 33(0)556-497-000 / contactbourse@europlasma.com
ARKEON Finance : Daniel RAYOT -
+33-01-53-70-29-45 - danielrayot@arkeonfinance.fr
CAPVALUE Samuel BEAUPAIN - Relations presse -
+33-01-80-81-50-05 - sbeaupain@capvalue.fr